Edgewise Therapeutics is a biopharmaceutical company focused on developing small molecule therapies for musculoskeletal diseases. Their lead product candidate, EDG-5506, aims to treat dystrophinopathies like Duchenne muscular dystrophy. The company is developing a pipeline of precision medicine products that target muscle proteins to address genetically defined muscle disorders. Founded in 2017, Edgewise Therapeutics is based in Boulder, Colorado.